Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

1. www.ncbi.nlm.nih.gov › pmc › articlesSystemic pharmacological treatments for chronic plaque psoriasis:...

   www.ncbi.nlm.nih.gov › pmc › articles

   13 Δεκ 2021 · Randomised controlled trials (RCTs) of systemic treatments in adults (over 18 years of age) with moderate‐to‐severe plaque psoriasis or psoriatic arthritis whose skin had been clinically diagnosed with moderate‐to‐severe psoriasis, at any stage of treatment, in comparison to placebo or another active agent.

2. www.jaad.org › article › S0190-9622(20)30284-XJoint American Academy of Dermatology–National Psoriasis...

   www.jaad.org › article › S0190-9622(20)30284-X

   28 Φεβ 2020 · This guideline provides detailed discussion and recommendations for the use of oral-systemic, nonbiologic medications for psoriasis, including methotrexate, cyclosporine, acitretin, tofacitinib, and apremilast. It also covers newer and older therapies, efficacy, safety, monitoring, and conflict of interest.

3. pubmed.ncbi.nlm.nih.gov › 35603936Systemic pharmacological treatments for chronic plaque psoriasis:...

   pubmed.ncbi.nlm.nih.gov › 35603936

   23 Μαΐ 2022 · Our review shows that, compared to placebo, the biologics infliximab, bimekizumab, ixekizumab, and risankizumab were the most effective treatments for achieving PASI 90 in people with moderate-to-severe psoriasis on the basis of high-certainty evidence.

4. onlinelibrary.wiley.com › doi › 10EuroGuiDerm Guideline on the systemic treatment of Psoriasis...

   onlinelibrary.wiley.com › doi › 10

   The overall aim of this guideline is to provide guidance for optimal treatment selection and management in the treatment of adults with moderate-to-severe plaque-type psoriasis. Optimal treatment selection and management are meant to reduce morbidity caused by psoriasis and to improve the health-related quality of life of affected individuals.

5. www.aafp.org › pubs › afpSystemic Pharmacologic Treatments for Plaque Psoriasis - AAFP

   www.aafp.org › pubs › afp

   • Αποθηκευμένο αντίγραφο

   Evidence-Based Answer. Infliximab, bimekizumab (Bimzelx), ixekizumab (Taltz), and risankizumab (Skyrizi) are the most effective medications for achieving a 90% reduction in symptoms...

6. pmc.ncbi.nlm.nih.gov › articles › PMC10337265Systemic pharmacological treatments for chronic plaque psoriasis:...

   pmc.ncbi.nlm.nih.gov › articles › PMC10337265

   Randomised controlled trials (RCTs) of systemic treatments in adults over 18 years with moderate‐to‐severe plaque psoriasis, at any stage of treatment, compared to placebo or another active agent.

7. www.ncbi.nlm.nih.gov › pmc › articlesSystemic pharmacological treatments for chronic plaque psoriasis:...

   www.ncbi.nlm.nih.gov › pmc › articles

   22 Δεκ 2017 · The aim of this review was to compare different systemic medicines (oral or injected medicines that work throughout the entire body) used to treat chronic plaque psoriasis in adults (over 18 years of age), to find out which are the safest and most effective at clearing psoriasis.